Isabella’s lung exam consist of a low-dose, non-contrast chest CT.

Here, the radiologist may face several challenges, such as a shortage of skilled staff, outdated technology, and prolonged interpretation times due to the lack of intelligent screening solutions.

However, in our case, the radiologist is supported: Thanks to an augmented reading aid the burden of basic repetitive tasks is reduced and diagnostic precision increased.

An AI-powered workflow solution detects and highlights Isabella’s lung nodules, has a multi-organ approach and helps not only in imaging lungs but also Isabella’s heart, aorta and spine. Yet, proper diagnosis and staging comprises more than a CT scan.

Based on the screening results, Isabella is referred to oncology with suspected lung cancer, as she presents not only small nodules (~ 5 mm) but also suspicious tissue (> 3 cm) in her lungs.

Isabella is referred to oncology with suspected lung cancer.

To further characterize Isabella's lesion and for pre-op staging, a biopsy needs to be taken and a PET/CT performed to visualize tumor activity.

In addressing these challenges, Biograph Vision.X plays a pivotal role. It offers highly accurate detection of Isabella's small lesions, providing essential guidance for both assessment and biopsy procedures. To mitigate the impact of breathing artifacts, AI powered technology, such as OncoFreeze AI, is harnessed to effectively freeze breathing motion without the need for a gating device.

Additionally, interventional CT and a mobile C-arm are employed to execute precise and targeted percutaneous biopsies, enhancing the accuracy of the diagnostic process.

In Isabella’s case, PET/CT provides highly detailed images of her small lesions for assessment and biopsy guidance. Interventional CT and a mobile C-arm are used to perform precise and targeted percutaneous biopsy.

Considering the results obtained with smart digital companions: What would be the optimal treatment regimen for Isabella’s NSCLC?

The critical question in Clinical Tumor Assessment is: How can you effectively assemble and present your patient’s intricate data in a limited time frame? The answer is Syngo Carbon.

Why? It empowers you to build seamless connections between departments. Its beauty lies in the ability to unite all clinical disciplines – from radiologists and oncologists, to surgeons, pathologists and nuclear medicine experts, and even beyond.

Thus, this imaging and reporting solution allows you to quickly compile and showcase Isabella’s data across modalities in one integrated and user-friendly workspace. In fact, Syngo Carbon equips you with a comprehensive 360° perspective that substantially enhances your decision-making in multidisciplinary conferences. It’s your connecting element that gives rise to knowledge to drive better patient outcomes. With Syngo Carbon all therapeutic resolutions are meticulously explored.

It's within this forum of shared expertise that the decision is shaped for Isabella’s optimal treatment.

Given the complex challenges posed by her lung cancer, Isabella requires comprehensive solutions driven by advanced systems. For early-stage patients surgery is indicated as the gold-standard. For high-risk patients radiotherapy is a good alternative.

The focus is on addressing small moving targets influenced by breathing patterns. The goal is to minimize harm to healthy tissue by minimally invasive treatment. Hence, advanced image guidance is employed to effectively execute the therapy. Hybrid surgical interventions involve both image-guided lesion marking and video-assisted wedge resection in a single session, aimed at reducing the time-at-risk for the patient significantly.⁴

In radiotherapy, special attention is given to protecting organs at risk with automatic contouring using deep-learning algorithms. Utilizing the only scanner adjusting to the patient’s breathing in real time, movement of the tumor with respiratory motion can be precisely understood and translated into precise treatment delivery on a linear accelerator.

Surgery or radiation: As a combined entity of Siemens Healthineers and Varian, we offer integrated imaging and therapy solutions for patients like Isabella at all stages of their lung health journey.

To detect potential recurrences early, we accompany patients like Isabella with a truly personalized cancer care follow-up processes. Three challenges have to be met: timely communication, medical data management, and thorough patient engagement.

The solution to improving survivorship worldwide is to empower patients like Isabella on their cancer care journey – with two digital tools: eHealth Virtual Visit is a telehealth application that offers seamless virtual consultation to transform care delivery and reduce the need for in-person visits.

Noona is a mobile app that enables patients to actively participate during their therapy & follow up. Through treatment insights, personalized education, and real-time recording of ePROs, the app fosters a collaborative approach to individualizing and optimizing post treatment care.

Thank you for accompanying Isabella on her Lung Health Journey. We are grateful that we were able to contribute to her fast diagnosis and successful treatment with our solutions.